Zevra Therapeutics Inc. announced the execution of an exclusive expanded access distribution agreement with Uniphar, an Ireland-based pharmaceutical services provider. The agreement enables Niemann-Pick Disease Type C (NPC) patients in select territories outside of Europe to access MIPLYFFA® (arimoclomol) through reimbursed named patient supply. MIPLYFFA is approved by the U.S. Food and Drug Administration and is commercially available in the U.S., with a Marketing Authorisation Application under review by the European Medicines Agency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617598-en) on December 29, 2025, and is solely responsible for the information contained therein.